Cancer Diagnosis
Diagnostic product
Femasys has achieved global regulatory approvals for a next generation diagnostic product for cervical cancer.
Cancer Diagnosis
Cervical cancer tissue sampling options have been the same for many decades. Although HPV vaccination is available, endocervical curettage is recommended for certain patients according to the National Institutes of Health.1
Every year in the U.S., 13,000 women get cervical cancer and 4,000 die of cervical cancer.2
As many as 93% of cervical cancers could be prevented by screening & HPV vaccination.3
- Massad et al. Colposcopy standards: Guidelines for Endocervical Curettage at Colposcopy. Journal of Lower Genital Tract Disease, Volume 27, Number 1, January 2023.
- https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html
- https://www.cdc.gov/vitalsigns/cervical-cancer/index.html
Our Cancer Diagnostic Product
Endocervical Biopsy
FemCerv, an FDA-cleared endocervical sampler, is the first to be designed for capture of a complete and uncontaminated sample in a relatively pain-free procedure. FemCerv features an expandable collection chamber that is exposed during sampling and closed during removal for containment of cervical cells and tissue.
FemCerv has regulatory approvals in the U.S. and Canada.
How it Works
